We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade Compared With Heparin and Planned Glycoprotein IIb/IIIa Blockade During Percutaneous Coronary Intervention: REPLACE-2 Randomized Trial.
- Authors
Lincoff, A. Michael; Bittl, John A.; Harrington, Robert A.; Feit, Frederick; Kleiman, Neal S.; Jackman, J. Daniel; Sarembock, Ian J.; Cohen, David J.; Spriggs, Douglas; Ebrahimi, Ramin; Keren, Gadi; Carr, Jeffrey; Cohen, Eric A.; Betriu, Amadeo; Desmet, Walter; Kereiakes, Dean J.; Rutsch, Wolfgang; Wilcox, Robert G.; de Feyter, Pim J.
- Abstract
The direct thrombin inhibitor bivalirudin has been associated with better efficacy and less bleeding than heparin during coronary balloon angioplasty but has not been widely tested during contemporary percutaneous coronary intervention (PCI). The purpose of this study was to determine the efficacy of bivalirudin, with glycoprotein IIb/IIIa (Gp IIb/IIIa) inhibition on a provisional basis for complications during PCI, compared with heparin plus planned Gp IIb/IIIa blockade with regard to protection from periprocedural ischemic and hemorrhagic complications. The Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)–2 trial, a randomized, double-blind, active-controlled trial conducted among 6010 patients undergoing urgent or elective PCI at 233 community or referral hospitals in 9 countries from October 2001 through August 2002. Patients were randomly assigned to receive intravenous bivalirudin (0.75-mg/kg bolus plus 1.75 mg/kg per hour for the duration of PCI), with provisional Gp IIb/IIIa inhibition (n = 2999), or heparin (65-U/kg bolus) with planned Gp IIb/IIIa inhibition (abciximab or eptifibatide) (n = 3011). Both groups received daily aspirin and a thienopyridine for at least 30 days after PCI. The primary composite end point was 30-day incidence of death, myocardial infarction, urgent repeat revascularization, or in-hospital major bleeding; the secondary composite end point was 30-day incidence of death, myocardial infarction, or urgent repeat revascularization. Provisional Gp IIb/IIIa blockade was administered to 7.2% of patients in the bivalirudin group. By 30 days, the primary composite end point had occurred among 9.2% of patients in the bivalirudin group vs 10.0% of patients in the heparin-plus-Gp IIb/IIIa group (odds ratio, 0.92; 95% confidence interval, 0.77-1.09; P = .32). The secondary composite end point occurred in 7.6% of patients in the...
- Subjects
ANTITHROMBINS; HEPARIN; POLYSACCHARIDES; ANTICOAGULANTS; ANGIOPLASTY; GLYCOPROTEINS
- Publication
JAMA: Journal of the American Medical Association, 2003, Vol 289, Issue 7, p853
- ISSN
0098-7484
- Publication type
Article
- DOI
10.1001/jama.289.7.853